INKT Stock Analysis: Buy, Sell, or Hold?
INKT - MiNK Therapeutics, Inc. Common Stock
$12.20
0.58 (4.99%)
▲
5d:
+8.25%
30d:
+17.76%
90d:
+11.52%
WAIT
LOW Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Aug 13, 2026
0d
Get Alerted When INKT Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: INKT shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: INKT shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: INKT is currently trading at $12.20, which is considered extended relative to its 30-day fair value range of $10.52 to $11.48.
Technical Outlook: Technically, INKT is showing sideways momentum. The price is approaching resistance at $12.20. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 5.0% recently.
Market Sentiment: INKT scores 33/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $39.00 (+219.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, INKT is showing sideways momentum. The price is approaching resistance at $12.20. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 5.0% recently.
Market Sentiment: INKT scores 33/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $39.00 (+219.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$10.52 -
$11.48
Company Quality Score
41/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
26.3%
All Signals
- BEARISH: Price extended above range (+6.3% above its trading range)
- BEARISH: Weak technical setup (33/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+5.0%)
- BULLISH: Trading 219.7% below Wall St target ($39.00)
- WARNING: Composite score 41/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$10.52 -
$11.48
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$10.80
Resistance Level
$12.20
Current Trend
Sideways
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-4.61
Wall Street Target
$39.00
(+219.7%)
Share & Embed Analysis
Last updated: August 24, 2026 8:46 AM ET
Data refreshes hourly during market hours. Next update: 9:46 AM
Data refreshes hourly during market hours. Next update: 9:46 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is INKT showing a specific setup today?
Insider Activity (6 Months)
0
Buys
4
Sells
Net
INSIDERS SELLING
Recent Transactions
Barbara Ryan
SELL
1300 shares
2026-03-10
Barbara Ryan
SELL
200 shares
2026-03-09
Barbara Ryan
SELL
100 shares
2026-03-02
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$91 | 42 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$285 | 66 BUY |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$35 | 50 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$108 | 52 HOLD |
|
MIRM
Mirum Pharmaceuticals Inc |
STRONG BUY
10 analysts |
$138 | 66 BUY |
